Krystal Biotech’s (KRYS) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Krystal Biotech (NASDAQ:KRYS) in a research report released on Thursday morning,Benzinga reports. The firm currently has a $215.00 target price on the stock.

A number of other analysts also recently issued reports on the company. Chardan Capital raised their target price on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research report on Thursday. HC Wainwright reissued a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a report on Wednesday. Finally, Citigroup upped their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Krystal Biotech presently has a consensus rating of “Buy” and a consensus price target of $210.00.

Krystal Biotech Stock Performance

Shares of NASDAQ:KRYS opened at $187.86 on Thursday. The company has a market capitalization of $5.41 billion, a P/E ratio of 62.83 and a beta of 0.84. The company’s 50-day moving average is $157.85 and its 200 day moving average is $175.28. Krystal Biotech has a fifty-two week low of $107.50 and a fifty-two week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm had revenue of $91.10 million for the quarter, compared to analysts’ expectations of $91.35 million. During the same period in the previous year, the company earned $0.30 earnings per share. The company’s quarterly revenue was up 116.4% on a year-over-year basis. As a group, research analysts predict that Krystal Biotech will post 6.14 earnings per share for the current year.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the transaction, the insider now directly owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 14.10% of the company’s stock.

Institutional Trading of Krystal Biotech

Several institutional investors and hedge funds have recently bought and sold shares of the company. FMR LLC grew its position in Krystal Biotech by 0.5% during the fourth quarter. FMR LLC now owns 4,314,014 shares of the company’s stock worth $675,833,000 after buying an additional 21,133 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Krystal Biotech by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company’s stock valued at $450,938,000 after acquiring an additional 28,707 shares during the last quarter. Avoro Capital Advisors LLC grew its holdings in shares of Krystal Biotech by 0.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company’s stock worth $411,831,000 after purchasing an additional 6,600 shares in the last quarter. State Street Corp increased its position in shares of Krystal Biotech by 9.0% in the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock worth $264,455,000 after purchasing an additional 119,936 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in Krystal Biotech by 2.0% in the third quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock valued at $107,714,000 after purchasing an additional 11,411 shares in the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).